Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma

Vox Sanguinis

Volumn 107, Issue 3, 2014, Pages 254-260

  Kwon, S Y ^a   Kim, I S ^b   Bae, J E ^b   Kang, J W ^a   Cho, Y J ^a   Cho, N S ^a   Lee, S W ^c  

^a Korean Red Cross   (South Korea)

^b Hannam University   (South Korea)

^c Korea Centers for Disease Control and Prevention   (South Korea)

Author keywords

Inactivation efficacy; Intercept blood system; Mirasol PRT system; Pathogen inactivation; Platelet concentrates

Indexed keywords

ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIAL INACTIVATION; BACTERIAL LOAD; BACTERIAL STRAIN; BLOOD COMPONENT; BLOOD TRANSFUSION; BOVINE VIRAL DIARRHEA VIRUS 1; DISEASE TRANSMISSION; ESCHERICHIA COLI; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PARVOVIRUS B19; INOCULATION; INTERCEPT BLOOD SYSTEM; LIMIT OF DETECTION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MIRASOL PATHOGEN REDUCTION SYSTEM; NONHUMAN; PATHOGEN INACTIVATION; PATHOGEN REDUCTION SYSTEM; PORCINE PARVOVIRUS; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; STAPHYLOCOCCUS AUREUS; THROMBOCYTE RICH PLASMA; VIRUS CAPSID; VIRUS INACTIVATION; VIRUS LOAD; VIRUS TITRATION; BACTERIUM; BLOODBORNE BACTERIUM; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; THROMBOCYTE; VIROLOGY; VIRUS;

BACILLUS SUBTILIS; BACTERIA; BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; HIV-1; HUMANS; MICROBIAL VIABILITY; PLATELET-RICH PLASMA; STAPHYLOCOCCUS AUREUS; VIRUS INACTIVATION; VIRUSES;

EID: 84925261240     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12158     Document Type: Article

References (26)

1. Schmidt M, Korn K, Nübling M, et al.: First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009; 49:1836-1844
2. Stramer SL, Hollinger FB, Katz LM, et al.: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49:1S-235S
3. Dreier J, Störmer M, Pichl L, et al.: Sterility screening of platelet concentrates: questioning the optimal test strategy. Vox Sang 2008; 95:181-188
4. Korea Centers for Disease Control & Prevention: Investigation of transfusion adverse reactions in Korea from 2007 to 2012. Public Health Weekly Report, KCDC 2012; 5:937-941
5. Korea Centers for Disease Control & Prevention: Transfusion-transmitted hepatitis A infection cases in Korea. Public Health Weekly Report, KCDC 2012; 5:713-717
6. Rasonglès P, Angelini-Tibert MF, Simon P, et al.: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009; 49:1083-1091
7. Osselaer JC, Doyen C, Defoin L, et al.: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412-1422
8. AABB: Listing of countries in which pathogen reduction technology systems and products are in routine use. http://www.aabb.org/resources/bct/eid/Documents/prt-systems-in-use-country-listing.pdf (downloaded 25th June 2013)
9. Lin L, Dikeman R, Molini B, et al.: Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44:1496-1504
10. Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885
11. Lin L, Hanson CV, Alter HJ, et al.: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580-590
12. Goodrich RP, Edrich RA, Li J: Seghatchian: the Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35:5-17
13. Brecher ME, Hay S, Corash L, et al.: Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. Transfusion 2007; 47:1896-1901
14. Goodrich RP, Gilmour D, Hovenga N, et al.: A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49:1205-1216
15. Tan LK, Lam S, Low SL, et al.: Evaluation of pathogen reduction systems to inactivate Dengue and Chikungunya viruses in apheresis platelets suspended in plasma. Adv Infect Dis 2013; 3:1-9
16. Epstein JS, Vostal JG: FDA approach to evaluation of pathogen reduction technology. Transfusion 2003; 43:1347-1350
17. Hamilton MA, Russo RC, Thurston RV: Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 1997; 11:714-719
18. Shin JS, Choi YW, Sung HM, et al.: Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol Bioprocess Eng 2006; 11:19-25
19. World Health Organization: Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924, 2004.
20. Goodrich RP, Custer B, Keil S, et al.: Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010; 50:1827-1837
21. Singh Y, Sawyer LS, Pinkoski LS, et al.: Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168-1177
22. Steiert M, Brussels A, Vandercappellen A, et al.: Evaluation of viral and bacterial inactivation in platelet concentrates suspended in 100% plasma treated with the Intercept Blood System. Vox Sang 2008; 95(Suppl. 1):301
23. Blümel J, Schmidt I, Willkommen H, et al.: Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42:1011-1018
24. Steinmann E, Gravemann U, Friesland M, et al.: Two pathogen reduction technologies -methylene blue plus light and shortwave ultraviolet light- effectively inactivate hepatitis C virus in blood products. Transfusion 2013; 53:1010-1018
25. Marschner S, Goodrich R: Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38:8-18
26. Chou ML, Wu YW, Su CY, et al.: Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang 2012; 102:277-284